Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Phase 1/2 Completed 93 enrolled Memorial Sloan Kettering Cancer Center Janssen Biotech, Inc. · collab Pharmacyclics LLC. · collab

Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to test any good or bad effects of the study drug called of ibrutinib (also known as Imbruvica™). At this stage of this trial, the study is investigating whether Ibrutinib can be incorporated into the established first-line chemotherapy regimen rituximab, methotrexate, vincristine, and procarbazine (R-VMP) in order to further refine the first-line induction therapy for PCNSL, as observed by a superior CRR (complete response rate) (ARM D RECRUITING ONLY)

Timeline

Start: 2014-12-08
Primary completion: 2026-01-28
Completion: 2026-01-28

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ibrutinib	Small molecule	420 mg	Oral
Subject	Ibrutinib	Small molecule	560 mg	Oral
Subject	Ibrutinib	Small molecule	840 mg	Oral
Background	Methotrexate	Small molecule	3.5 mg/m2	—
Background	Rituximab	Monoclonal antibody	500 mg/m2	Intravenous
Background	procarbazine	Small molecule	100 mg/m2	Oral

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Summary

Timeline

Publications

Drugs

Indications